In summary, RBM15 drives HCC progression by enhancing angiogenesis through VEGFA stabilization and by mediating HBx-induced circRNA degradation, collectively establishing RBM15 as both a tumor promoter and a potential therapeutic target in liver cancer. This evidence concerns the gene VEGFA and hepatocellular carcinoma.